COPD and Pneumonia Study (CAP)

STUDY COMPLETED and REPORTED


Did you know that you have a six to eight times greater risk of developing pneumonia if you have COPD?

Since COPD patients are at greater risk for developing pneumonia, we wanted to better understand the impact pneumonia has on the lives of our COPD community. Understanding the burden of pneumonia on the COPD community is important to help inform public health and prevention measures. Help us understand the burden of community acquired pneumonia by joining the online COPD and Pneumonia (CAP) study that was conducted through the COPD Patient-Powered Research Network (COPD PPRN).


This was the first completed study using the COPD PPRN platform which provided proof of concept for using this COPD360 Registry for surveys

The objectives of this study were to

 

  1. assess the symptom burden of CAP

  2. report time to symptom recovery

  3. assess the impact of CAP on daily activities from the COPD patient perspective


The study surveyed nearly 500 individuals with COPD who had also recently received a Community Acquired Pneumonia (CAP) diagnosis, and concluded that individuals with COPD suffering from CAP will miss an average of 21 days from work with an additional 14 days required to return to “usual” job performance, will be impaired from normal activities for more than 30 days and experience weeks of lingering symptoms.

The results show that all the COPD-CAP-diagnosed participants experienced multiple symptoms including cough, breathlessness, and fatigue, often requiring weeks to recover and resulting in missing work and participation in usual activities. Over 84% reported requiring assistance from family and friends. The symptom and resulting burden were greater and lasted for a longer period than reported in the general community of CAP diagnosed individuals without COPD accessed in previous CAP studies.

Conclusion:

CAP causes a major burden in individuals with COPD their families and caregivers and it is important to ensure CAP prevention strategies including smoking cessation support and immunizations.

The results were reported in Pasquale CB, Vietri J, Choate R, et al. Patient-reported consequences of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019; 6(2): 132-144.

A link to the publication: http://doi.org/10.15326/jcopdf.6.2.2018.0144

The CAP study was funded and sponsored by Pfizer and operationalized by the COPD Foundation through the PPRN.